Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 4/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | TLR4 | O00206 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249769 | 1.00 | ALDH1A1 (0.49) | ALDH1A1GAATSHRPREPDPP4 | |
| SCHEMBL3731016 | 0.88 | ALDH1A1 (0.47) | ALDH1A1GAATSHRPREPDPP4 | |
| SCHEMBL3731023 | 0.88 | ALDH1A1 (0.47) | ALDH1A1GAATSHRPREPDPP4 | |
| SCHEMBL3745092 | 0.87 | ALDH1A1 (0.46) | ALDH1A1GAATSHRPREPDPP4 | |
| SCHEMBL3745098 | 0.87 | ALDH1A1 (0.46) | ALDH1A1GAATSHRPREPDPP4 | |
| SCHEMBL3743161 | 0.87 | ALDH1A1 (0.45) | ALDH1A1GAATSHRPREPDPP4 | |
| SCHEMBL3743156 | 0.87 | ALDH1A1 (0.45) | ALDH1A1GAATSHRPREPDPP4 | |
| SCHEMBL2785645 | 0.86 | CCR2 (0.49) | ALDH1A1GAATSHRPREPCTSK | |
| SCHEMBL2785651 | 0.86 | CCR2 (0.49) | ALDH1A1GAATSHRPREPCTSK | |
| SCHEMBL3249696 | 0.84 | PREP (0.45) | ALDH1A1GAATSHRPREPCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049519-B9 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2049519-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-05-12 | — | — | EP | disclosed |
| US-7687508-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080027080-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027080-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR5, CXCR4, CCR7 | ALDH1A1 2503/4885GAA 3481/4885TSHR 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.